© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 1, 57-59,
January 3, 2001
© 2001 Oxford University Press
BRIEF COMMUNICATION |
-Difluoromethylornithine and Polyamine Levels in the Human Prostate: Results of a Phase IIa Trial
Affiliations of authors: A. R. Simoneau, Veterans Administration Hospital, Long Beach, CA, and Department of Surgery and Chao Family Comprehensive Cancer Center, University of California, Irvine; E. W. Gerner, Departments of Radiation Oncology and Biochemistry and Arizona Cancer Center, University of Arizona, Tucson; M. Phung, Chao Family Comprehensive Cancer Center, University of California, Irvine; C. E. McLaren, F. L. Meyskens, Jr., Department of Medicine and Chao Family Comprehensive Cancer Center, University of California, Irvine.
Correspondence to: Frank L. Meyskens, Jr., M.D., Chao Family Comprehensive Cancer Center, 101 The City Dr., Orange, CA 92868 (e-mail: flmeyske@uci.edu).
Prostate cancer is the most commonly diagnosed malignancy in men and the second leading cause of male cancer deaths in the United States (1). As such, the prevention of prostate cancer is of national medical concern. One approach to prevention of prostate cancer is to suppress the polyamine levels in the prostate, an avenue suggested by studies indicating that ornithine decarboxylase (ODC), the first enzyme in the polyamine pathway, is overexpressed in human prostate cancer tissue (2) and is the target enzyme for 
-difluoromethylornithine (DFMO). This inhibitor suppresses tissue contents of polyamines, which are required for optimal cell proliferation and differentiation.
Elevated levels of polyamine are associated with several malignant or premalignant lesions (3–5). Prostate cancer seems a logical organ system for DFMO chemoprevention, since ODC activity and polyamine content are higher in prostatic
NOTES
REFERENCES
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. A. Zell, A. Ziogas, N. Ignatenko, J. Honda, N. Qu, A. S. Bobbs, S. L. Neuhausen, E. W. Gerner, and H. Anton-Culver Associations of a Polymorphism in the Ornithine Decarboxylase Gene with Colorectal Cancer Survival Clin. Cancer Res., October 1, 2009; 15(19): 6208 - 6216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Simoneau, E. W. Gerner, R. Nagle, A. Ziogas, S. Fujikawa-Brooks, H. Yerushalmi, T. E. Ahlering, R. Lieberman, C. E. McLaren, H. Anton-Culver, et al. The Effect of Difluoromethylornithine on Decreasing Prostate Size and Polyamines in Men: Results of a Year-Long Phase IIb Randomized Placebo-Controlled Chemoprevention Trial Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 292 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-T. Vlastos, L. A. West, E. N. Atkinson, I. Boiko, A. Malpica, W. K. Hong, and M. Follen Results of a Phase II Double-Blinded Randomized Clinical Trial of Difluoromethylornithine for Cervical Intraepithelial Neoplasia Grades 2 to 3 Clin. Cancer Res., January 1, 2005; 11(1): 390 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. Wattenberg, T. S. Wiedmann, and R. D. Estensen Chemoprevention of Cancer of the Upper Respiratory Tract of the Syrian Golden Hamster by Aerosol Administration of Difluoromethylornithine and 5-Fluorouracil Cancer Res., April 1, 2004; 64(7): 2347 - 2349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Y. Y. Fong, D. J. Feith, and A. E. Pegg Antizyme Overexpression in Transgenic Mice Reduces Cell Proliferation, Increases Apoptosis, and Reduces N-Nitrosomethylbenzylamine-induced Forestomach Carcinogenesis Cancer Res., July 15, 2003; 63(14): 3945 - 3954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Rhodes, T. R. Barrette, M. A. Rubin, D. Ghosh, and A. M. Chinnaiyan Meta-Analysis of Microarrays: Interstudy Validation of Gene Expression Profiles Reveals Pathway Dysregulation in Prostate Cancer Cancer Res., August 1, 2002; 62(15): 4427 - 4433. [Abstract] [Full Text] [PDF]
|
|